Abstract: An object of the invention is to provide a mucoadhesive oral preparation having high drug absorption rate and rapid drug release rate. The means for solving the problem is a mucoadhesive oral preparation having (a) a basal layer substantially consisting of a water-insoluble material, (b) a drug layer locating above the basal layer and containing a drug but not containing mucoadhesive material, and (c) an adhesive portion locating on a portion of the surface of the drug layer side of the oral formulation and containing mucoadhesive material.

Abstract: The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers, savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

Abstract: This invention relates to high-water oral care compositions comprising a basic amino acid or salt thereof, together with a precipitated calcium carbonate, glycerol, and to methods of using and of making these compositions.

Abstract: The present invention relates to a method of a) treating any of depression induced by chronic stress; depression in a subject afflicted with PTSD; anxiety induced by chronic stress; anxiety in a subject afflicted with PTSD; cognitive impairment induced by chronic stress; altered morphology and/or reduced number of GFAP+ cells in hippocampus and/or frontal cortex induced by chronic stress; working memory impairment in a subject afflicted with PTSD; b) inhibiting or reversing loss of GFAP+ cells in hippocampus and/or frontal cortex induced by chronic stress; c) decreasing consolidation of contextual fear memory in a subject afflicted with PTSD; d) enhancing extinction of fear memory in a subject afflicted with PTSD; or e) increasing calcineurin A expression in a subject afflicted with PTSD using a combination of cotinine and an antioxidant.

Abstract: The present invention provides a liposome useful as a vaccine adjuvant. More specifically, the present invention provides a liposome which comprises a lipid bilayer comprising dimyristoylphosphatidylcholine and egg phosphatidylglycerol and a conjugated compound in which a low-molecular weight compound enhancing the physiological activity of TLR7 is bound to squalene via a linker, said conjugated compound being encapsulated in the lipid bilayer.

Abstract: The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets.

Abstract: Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

Abstract: Described herein is an invention that includes a spreadable conditioning composition comprising a blend of: a branched hydrocarbon and an ester having a kinematic viscosity of less than or equal to about 100 centistokes. The composition may be natural, for example, if each of the branched hydrocarbon and the ester are independently vegetable-derived. In addition, the composition may lack ingredients that are derived from a palm oil. In an embodiment, the composition is a blend of hydrogenated farnesene and an esters selected from glyceryl triheptanoate, dicapryl succinate, heptyl undecylenate, and mixtures thereof. The composition exhibits an average spreading velocity of about 4 to about 8. Also disclosed are formulations for use in products of personal care, home/institutional care, industry, pharmaceutical and medical and veterinary care and related methods.

Abstract: Disclosed are antimicrobial releasing agents, methods of preparing the antimicrobial releasing agents, and entrained polymers containing antimicrobial releasing agents. The antimicrobial releasing agent is prepared with an acidified hydrophilic material with a pH below 3.5 as a carrier, an active compound, and a trigger. The entrained polymer of the invention releases an antimicrobial agent in gas form, such as ClO2, optionally over a range of concentration from 150 ppm to 1800 ppm per gram of the entrained polymer under certain tested conditions.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: The drug-containing fat emulsion of the present invention, which comprises at least a slightly water soluble drug, an oil or fat, an emulsifier, and water as components, is characterized by having a content of the oil or fat of 2 to 120 mg/mL (excluding 2 mg/mL), having a weight ratio of the drug to the oil or fat (drug/(oil or fat)) of 0.001 to 20 (provided that the total content of the drug and the oil or fat is at most 125 mg/mL), having a content of lecithin as the emulsifier of 50 to 200 mg/mL (in which 50% by weight or less of the used lecithin is optionally replaced by an emulsifier other than lecithin), and having a turbidity of 0.5 or lower.

Abstract: The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.

Abstract: Non-aqueous dentifrice compositions comprising an alkaline earth metal acetate salt such as strontium acetate and/or an alkaline earth metal nitrate salt such as strontium nitrate; a carboxyvinyl polymer and a humectant.

Abstract: Stable wood preservative formulations comprising an amine copper complex, an azole compound, a cationic surfactant, and optionally, an organic solvent, are disclosed. The wood preservative formulations exhibit long-term stability and remain homogeneous, without the need for agitation.

Abstract: Oral care compositions and methods for the same are provided herein. The oral care composition may include an orally acceptable vehicle, a peroxide whitening agent, and one or more gelling agents. The gelling agents may include a fatty acid. The gelling agents may be free or substantially free of fatty alcohols. The gelling agents may include at least one of palmitic acid, stearic acid, or mixtures thereof.

Abstract: Provided are surprisingly effective methods for inactivating pathogens, and for producing highly immunogenic vaccine compositions containing an inactivated pathogen rendered noninfectious by exposure to a Fenton reagent, or by exposure to a Fenton reagent or a component thereof in combination with a methisazone reagent selected from the group consisting of methisazone, methisazone analogs, functional group(s)/substructure(s) of methisazone, and combinations thereof. The methods efficiently inactivate pathogens, while substantially retaining pathogen antigenicity and/or immunogenicity, and are suitable for inactivating pathogens, or for the preparation of vaccines for a wide variety of pathogens with genomes comprising RNA or DNA, including viruses and bacteria. Also provided are highly immunogenic inactivated vaccine compositions prepared by using any of the disclosed methods, and methods for eliciting an immune response in a subject by administering such vaccine compositions.

Abstract: An oral care composition with tin, polyol with five or more carbon atoms, water, and a pH of greater than 7. An oral care composition with a tin ion source, a fluoride ion source, a polyol with five or more carbon atoms, water, and a pH of greater than 7. Oral care compositions with a high tin ion availability.

Abstract: A dentifrice composition with tin, calcium, and a pH of greater than 7. A dentifrice composition with tin, fluoride, calcium abrasive, water, and a pH of greater than 7. Dentifrice compositions with a high tin ion availability. Dentifrice compositions comprising stannous fluoride and/or stannous chloride in combination with calcium carbonate.

Abstract: An oral care composition with a tin, polyol with five or six carbon atoms, polyol with seven or more hydroxyl functional groups, and a pH of greater than 7. An oral care composition with a tin ion source, a fluoride ion source, a polyol with five or six carbon atoms, a non reducing sugar or sugar alcohol with seven or more hydroxyl functional groups, and a pH of greater than 7. Oral care compositions with a high tin ion availability.

Abstract: The invention is directed to hierarchical aluminosilicates that contain both micro- and meso-pores, to methods for loading and delivering poorly soluble antioxidants such as CoQ10 and curcumin to subjects, and to a top-down method for producing hierarchical aluminosilicates.